View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 3, 2020updated 12 Jul 2022 11:34am

Novartis’ migraine medicine trial meets endpoints

Novartis has announced that first Phase IV HER-MES study of Aimovig (erenumab) against topiramate in patients with episodic and chronic migraine met its primary and secondary endpoints. 

Novartis has announced that first Phase IV HER-MES study of Aimovig (erenumab) against topiramate in patients with episodic and chronic migraine met its primary and secondary endpoints.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Aimovig is designed to target the calcitonin gene-related peptide (CGRP) receptor associated with migraine. It is jointly marketed by Amgen and Novartis in the US.

The two-armed, randomised, double-blind, double-dummy, head-to-head, parallel group study analysed the tolerability and efficacy of Aimovig 70mg and 140mg versus topiramate, an anticonvulsant, in a patient-centred setting.

It enrolled 777 adult patients with episodic or chronic migraine who were naïve to, not suitable for, or had previously failed up to three prophylactic migraine treatments with propranolol/metoprolol, amitriptyline and flunarizine.

The results of the study showed that Aimovig demonstrated superior tolerability and efficacy profile than topiramate. The therapy showed less discontinuation over the course of the 24-week treatment phase, meeting the trial’s primary endpoint.

Aimovig also showed superior efficacy, with a greater proportion of patients achieving at least 50% reduction in their monthly migraine days (MMDs), meeting the secondary endpoint.

Novartis Pharmaceuticals Neuroscience Medical Affairs global head Estelle Vester-Blokland said: “With Aimovig continuing to be the anti-CGRP treatment with the longest safety and efficacy experience, these results further emphasize its potential to provide significant relief from migraine with an infrequent dosing compared with the oral treatment.”

Fully developed in Germany, the HER-MES study was conducted across 82 centres from February end last year to July end this year.

Aimovig’s safety profile in the study was consistent with those seen in previous ones.

Last month, Amgen reported positive long-term data from a Phase II trial of Aimovig in patients with episodic migraine.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena